iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Core Insights - iBio, Inc. is advancing its research on the Activin E antibody, IBIO-610, which shows promise as a differentiated treatment for obesity, potentially offering fat-selective weight loss and enhancing GLP-1 therapies [2][6] - The company will present findings at two significant conferences: ObesityWeek 2025 and PEGS Europe 2025, highlighting its innovative approaches in obesity treatment [1][4] Presentation Details - At ObesityWeek 2025, Cory Schwartz will present on November 4, 2025, discussing the discovery and testing of a first-in-class Activin E antagonist antibody for obesity treatment [3] - Martin Brenner will present at PEGS Europe 2025 on November 12, 2025, focusing on the fat-selective weight loss induced by the anti-Activin E antibody in diet-induced obese mice [4] Company Overview - iBio, Inc. utilizes AI and advanced computational biology to develop biopharmaceuticals targeting cardiometabolic diseases, including obesity and cancer [4] - The company aims to transform drug discovery and accelerate development timelines through proprietary 3D modeling and innovative drug discovery platforms [4]